Last reviewed · How we verify

Docetaxel + LH-RH analogues — Competitive Intelligence Brief

Docetaxel + LH-RH analogues (Docetaxel + LH-RH analogues) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane chemotherapy + GnRH agonist combination. Area: Oncology.

phase 3 Taxane chemotherapy + GnRH agonist combination Microtubules (docetaxel); GnRH receptor (LH-RH analogues) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel + LH-RH analogues (Docetaxel + LH-RH analogues) — University of Turin, Italy. Docetaxel inhibits microtubule depolymerization to arrest cancer cell division, while LH-RH analogues suppress testosterone production to reduce androgen-dependent tumor growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Docetaxel + LH-RH analogues TARGET Docetaxel + LH-RH analogues University of Turin, Italy phase 3 Taxane chemotherapy + GnRH agonist combination Microtubules (docetaxel); GnRH receptor (LH-RH analogues)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane chemotherapy + GnRH agonist combination class)

  1. University of Turin, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel + LH-RH analogues — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-lh-rh-analogues. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: